High cost drugs
نویسندگان
چکیده
منابع مشابه
High cost of new drugs.
he investigation by The BMJ and Cambridge and Bath universities into the availability of breakthrough hepatitis C drugs raises important questions for NHS England about access to lifesaving drugs. But why are medicines so expensive in the first place? The pricing strategy of Gilead for sofosbuvir (Sovaldi) and ledipasvir-sofosbuvir (Harvoni) raises questions that go well beyond the UK. The BMJ'...
متن کاملInequalities in oncology care: Economic consequences of high cost drugs.
The expenditures for hospital drugs are continuously increasing, and grow much faster than the global hospital budgets do. This explosive growth is caused mainly by a few so-called 'expensive drugs' of which the oncolytics form the main part. The global budgets should stimulate more effective provision of care ('technical efficiency'), however the room for technical efficiency is decreasing. Ho...
متن کاملPatents Associated with High-Cost Drugs in Australia
Australia, like most countries, faces high and rapidly-rising drug costs. There are longstanding concerns about pharmaceutical companies inappropriately extending their monopoly position by "evergreening" blockbuster drugs, through misuse of the patent system. There is, however, very little empirical information about this behaviour. We fill the gap by analysing all of the patents associated wi...
متن کاملLowering the High Cost of Cancer Drugs--II.
EU Government brings cost of hepatitis C drug to V5,000 below list price, published 21st November 2014, PMLIVE website. http://www. pmlive.com/pharma_news/france_agrees_lowest_ sovaldi_pricing_in_eu_618661. Accessed January 22, 2016. 9. Messori A. Spend less on drug enforcement and more on treating hepatitis C, say campaigners [response]. BMJ website. http://www.bmj.com/ content/346/bmj.f3428/r...
متن کاملReimbursement of new high cost drugs--funding the unfundable?
Expenditure under the Community Drugs Schemes exceeded 1.9 billion in 2008, a five fold increase over the decade 1998 â 2008. The scheme with the greatest year on year increase in expenditure is the High Tech Drug Scheme accounting for 290 million in 2008. This scheme will come under greater pressure with the advent of very high cost drugs such as eculizumab (Soliris) for the treatment of...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of prescribing practice
سال: 2021
ISSN: ['2631-8385', '2631-8393']
DOI: https://doi.org/10.12968/jprp.2021.3.9.350